This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Adverse event reporting can be found at the bottom of the page
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
For TALZENNA® (talazoparib) Prescribing Information click here.
The content of this website has been produced in line with the Talzenna Summary of Product Characteristics for the United Kingdom. Talzenna (talazoparib) Prescribing Information for The United Kingdom click here. Adverse event reporting information can be found at the bottom of the page.
The video highlights the combination of talazoparib, a PARP inhibitor, with enzalutamide, an androgen receptor inhibitor, which enhances treatment efficacy by preventing cancer cells from repairing their DNA, leading to cell death.
How do PARPi and ARPi work together?
The interaction of PARP inhibitors and AR inhibitors, has the ability to elicit anti-tumour effects, independent of initial HRR gene status.1, 2
PARP (poly ADP-ribose polymerase) inhibitors have traditionally been used in HRR-deficient cells to impair the cellular detection of DNA damage. Preclinical data have demonstrated interdependencies between the androgen receptor (AR) and PARP that could be therapeutically exploited by combining PARP inhibitors and AR pathway inhibitors, irrespective of HRR deficiencies. Coadministration of these treatments may lead to substantial clinical benefit, possibly delay resistance, and provide an additional therapeutic treatment for men with mCRPC.1
Please refer to the enzalutamide Summary of Product Characteristics (SmPC) for recommended dosing information about enzalutamide.
Stay up to date with the latest relevant healthcare, medical and promotional information from Pfizer by email.
Abbreviations:
MOA - Mechanism of Action, mCRPC - Metastatic Castration-Resistant Prostate Cancer, PARPi - Poly ADP-ribose Polymerase, ARPi - Androgen Receptor Inhibitor, AR - Androgen Receptor, DNA - Deoxyribonucleic Acid, HRR - Homologous Recombination Repair, DSBs - Double-Stranded Breaks, SSB - Singe-Stranded Break
1. TALZENNA® (talazoparib) Summary of Product Characteristics for United Kingdom. Available on www.medicines.org.uk
2. Agarwal N, Azad AA, Carles J, et al. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial. Lancet 2023;1-13. [Accessed: May 2025].
PP-TXT-GBR-0035 May 2025
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2026 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-UNP-GBR-13971. December 2025